Eurobio Scientific Faces Mandatory Squeeze-Out After Buyout Offer
Eurobio Scientific disclosed a public withdrawal offer followed by a mandatory squeeze-out targeting remaining shareholders, according to a Sept. 24 filing.
Eurobio Scientific, a French diagnostics company listed on Euronext, announced on September 24, 2026, the filing of a public withdrawal offer to be followed by a mandatory squeeze-out procedure targeting the firm's outstanding shares, according to a regulatory communiqué released Wednesday.
The dual-stage process — known in French securities law as an offre publique de retrait suivie d'un retrait obligatoire — is a standard mechanism used when a controlling shareholder has accumulated a dominant stake and seeks to fully delist a company by acquiring remaining minority-held shares at a set price.
Read more Bybit Launches 'Make Your Move' Global Brand Campaign →
The filing signals that the controlling party has met the ownership threshold required under French financial market regulations to compel minority shareholders to tender their remaining shares, effectively ending Eurobio Scientific's status as a publicly traded company. French market regulator AMF typically oversees and must approve such procedures before they take effect.
The announcement marks a significant milestone in the consolidation of Eurobio Scientific's ownership structure. Minority shareholders subject to the squeeze-out are generally entitled to receive the offer price established during the withdrawal offer phase, though they have limited recourse to block the transaction once the regulatory threshold has been crossed.
Full details of the offer terms and the applicable timetable were expected to be set out in documentation submitted to the AMF in connection with the filing. Continue reading at GlobeNewswire - Industry News on Financial Services.
